AU2002243439A1 - Fatty acid synthase inhibitors - Google Patents
Fatty acid synthase inhibitorsInfo
- Publication number
- AU2002243439A1 AU2002243439A1 AU2002243439A AU2002243439A AU2002243439A1 AU 2002243439 A1 AU2002243439 A1 AU 2002243439A1 AU 2002243439 A AU2002243439 A AU 2002243439A AU 2002243439 A AU2002243439 A AU 2002243439A AU 2002243439 A1 AU2002243439 A1 AU 2002243439A1
- Authority
- AU
- Australia
- Prior art keywords
- fatty acid
- acid synthase
- synthase inhibitors
- inhibitors
- fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000015303 Fatty Acid Synthases Human genes 0.000 title 1
- 108010039731 Fatty Acid Synthases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24964700P | 2000-11-17 | 2000-11-17 | |
| US60/249,647 | 2000-11-17 | ||
| PCT/US2001/051330 WO2002055661A2 (en) | 2000-11-17 | 2001-11-16 | Fatty acid synthase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002243439A1 true AU2002243439A1 (en) | 2002-07-24 |
Family
ID=22944400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002243439A Abandoned AU2002243439A1 (en) | 2000-11-17 | 2001-11-16 | Fatty acid synthase inhibitors |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002243439A1 (en) |
| WO (1) | WO2002055661A2 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008075077A1 (en) * | 2006-12-21 | 2008-06-26 | Astrazeneca Ab | Piperidine derivatives for the treatment of obesity |
| TW200833663A (en) * | 2006-12-21 | 2008-08-16 | Astrazeneca Ab | Therapeutic agents |
| EP2615918A4 (en) * | 2010-09-17 | 2014-01-29 | Glaxosmithkline Ip Dev Ltd | Fatty acid synthase inhibitors |
| SG11201507486SA (en) | 2013-03-13 | 2015-10-29 | Forma Therapeutics Inc | Novel compounds and compositions for inhibition of fasn |
| CA3023040A1 (en) | 2016-05-30 | 2017-12-07 | Technische Universitat Munchen | Urea motif containing compounds and derivatives thereof as antibacterial drugs |
| TWI767148B (en) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | Inhibiting fatty acid synthase (fasn) |
| CN113382633A (en) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | Solid forms of (4- (2-fluoro-4- (1-methyl-1H-benzo [ d ] imidazol-5-yl) benzoyl) piperazin-1-yl) (1-hydroxycyclopropyl) methanone |
-
2001
- 2001-11-16 AU AU2002243439A patent/AU2002243439A1/en not_active Abandoned
- 2001-11-16 WO PCT/US2001/051330 patent/WO2002055661A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002055661A3 (en) | 2003-02-13 |
| WO2002055661A2 (en) | 2002-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001258771A1 (en) | -secretase inhibitors | |
| IL153230A0 (en) | Liposomal benzoquinazoline thymidylate synthase inhibitor formulations | |
| AU2002219555A1 (en) | VLA-4 Inhibitors | |
| AU2001237041A1 (en) | Kinase inhibitors | |
| AU2001270200A1 (en) | Fatty acid synthase inhibitors | |
| AU2001278986A1 (en) | 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors | |
| AU2001281059A1 (en) | Fatty acid synthase inhibitors | |
| AU2001236052A1 (en) | Urease inhibitors | |
| AU2001280167A1 (en) | Novel propenohydroxamic acid derivatives | |
| AU2002222627A1 (en) | Tak1 inhibitors | |
| AU7961300A (en) | Kainic acid neurocytotoxicity inhibitors | |
| IL148324A0 (en) | Fatty acid synthase inhibitors | |
| AU2001271531A1 (en) | Fatty acid synthase inhibitors | |
| AU2003902413A0 (en) | Modification of fatty acid biosynthesis | |
| AU2002224550A1 (en) | Corrosion inhibitors | |
| GB0030284D0 (en) | Enzyme inhibitors | |
| AU2002243439A1 (en) | Fatty acid synthase inhibitors | |
| AU2001274940A1 (en) | Fatty acid synthase inhibitors | |
| IL151250A0 (en) | Difluorobutyric acid metalloprotease inhibitors | |
| AU6925500A (en) | Fatty acid synthase inhibitors | |
| AU2001271718A1 (en) | Fatty acid synthase inhibitors | |
| AU6926500A (en) | Fatty acid synthase inhibitors | |
| AU2001284705A1 (en) | Fatty acid synthase inhibitors | |
| AU2001291160A1 (en) | Fatty acid synthase inhibitors | |
| AUPQ851000A0 (en) | Rapid fatty acid delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |